Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anedol-SP is a multi-action fixed-dose combination analgesic and anti-inflammatory tablet marketed by MetaneX Life Science. It typically contains three active ingredients: aceclofenac, paracetamol (acetaminophen), and serratiopeptidase. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that preferentially inhibits cyclooxygenase-2 (COX-2) to reduce the production of prostaglandins involved in pain and inflammation. Paracetamol acts as an analgesic and antipyretic, likely through central nervous system mechanisms and weak inhibition of prostaglandin synthesis. Serratiopeptidase is a proteolytic enzyme that helps reduce inflammation and edema by breaking down fibrin and other proteins at the site of injury, thereby improving tissue repair. This combination is widely used for the management of pain and swelling associated with bone and joint disorders like rheumatoid arthritis and osteoarthritis, as well as post-operative inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anedol-SP.